60/100B40.920
USD
0.22
(0.53%)
Market Open
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.68Revenue estimate 11.78B
Q4 FY2026 · Earnings report
EPS estimate 0.68Revenue estimate 11.78B
If you had invested in Novo-Nordisk A/S ago, it would be worth $2,969 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
60/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Novo-Nordisk A key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Value stock · 7.9/10Growth 4.4 · Value 7.9 · Dividend 6.2
- Day range
- 40.650 – 41.060
- 52-week range
- 35.120 – 64.160
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 180.39B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 10.87
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.25
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 3.76
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 2.83%
- EPS growth forecast (FY2026)
- -13.3%
- Volume
- 24,448
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.35
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 62.9/100Environment 57 · Social 61 · Governance 70
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar
- Employees
- 69K
- Website
- novonordisk.com
- IPO date
- 30 Apr 1981
Novo-Nordisk A earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.68 USD
Revenue estimate
11.78B USD
Last quarter · Q3 FY2026
EPS0.89Beat +21.8%Revenue11.90BBeat +7.5%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 0.68 | — | — | -32.00% | 11.78B | — | — | -5.75% | |
| Q3 FY2026 | 0.73 | 0.89 | +21.75% | -12.75% | 11.07B | 11.90B | +7.54% | +3.25% | |
| Q2 FY2026 | 0.82 | 0.96 | +17.07% | -1.03% | 10.89B | 12.13B | +11.40% | +1.30% | |
| Q1 FY2026 | 0.87 | 1.04 | +19.54% | +13.04% | 10.86B | 11.02B | +1.50% | -7.35% | |
| Q4 FY2025 | 0.90 | 1.00 | +11.11% | +9.89% | 12.13B | 12.50B | +3.10% | +5.44% | |
| Q3 FY2025 | 0.77 | 1.02 | +32.47% | +15.91% | 11.94B | 11.53B | -3.47% | +7.93% | |
| Q2 FY2025 | 0.93 | 0.97 | +4.30% | +47.64% | 11.92B | 11.97B | +0.43% | +22.19% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 3.62 | — | — | +8.13% | 49.34B | — | — | +5.93% |
| FY2027 | 3.34 | — | — | -1.38% | 46.58B | — | — | +1.80% |
| FY2026 | 3.39 | — | — | -13.28% | 45.75B | — | — | -4.49% |
| FY2025 | 3.70 | 3.91 | +5.74% | +19.72% | 48.38B | 47.90B | -0.99% | +14.81% |
| FY2024 | 3.13 | 3.27 | +4.20% | +20.96% | 39.71B | 41.72B | +5.08% | +23.22% |
| FY2023 | 2.68 | 2.70 | +0.66% | +56.07% | 33.59B | 33.86B | +0.81% | +37.91% |
| FY2022 | 1.75 | 1.73 | -1.19% | +4.22% | 25.29B | 24.55B | -2.91% | +11.68% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Novo-Nordisk A analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
42.33 USD
+3.45%
Analysts' 1-year price targets range from 40.00 to 47.00, with an average of 42.33.
Past year
1-year forecast
Strong sellStrong buy
Hold
6 ratings
| Buy | 0 | |
| Hold | 5 | |
| Sell | 1 |
12-month price target
| Highest target | 47.00 |
| Average target | 42.33 |
| Lowest target | 40.00 |
| Current price | 40.92 |
Novo-Nordisk A valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 10.87
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 12.07
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 3.66
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 5.60
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 7.06
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
180.39B USD
+
Total debt
19.88B USD
−
Cash and short-term investments
7.27B USD
=
Enterprise value
193.00B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Novo-Nordisk A against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Pfizer, Gilead Sciences, Bristol-Myers Squibb, Amgen, Merck & Co., and AbbVie, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median10.99.350.6
- Gross marginLowest in 5 years81.0%81.0%84.7%Against its peers: 1 of 7Peers' median 71.5%
- Operating marginLowest in 5 years41.3%41.3%44.2%Against its peers: 1 of 7Peers' median 31.0%
- Net marginBelow its median33.1%31.4%36.0%Against its peers: 1 of 7Peers' median 17.8%
- Return on equityLowest in 5 years52.8%52.8%78.5%Against its peers: 2 of 6Peers' median 37.5%
- Free cash flow marginLowest in 5 years9.4%9.4%36.2%Against its peers: 7 of 7Peers' median 24.3%
- Revenue growthLowest in 5 years6.4%6.4%31.3%Against its peers: 3 of 7Peers' median 1.8%
- EPS growthLowest in 5 years1.8%1.8%52.4%Against its peers: 4 of 6Peers' median 8.0%
- Debt to EBITDAHighest in 5 years0.84×0.24×0.84×Against its peers: 1 of 7Peers' median 3.16×
- Current ratioBelow its median0.800.740.89Against its peers: 6 of 7Peers' median 1.21
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Novo-Nordisk A growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 333.14B DKK
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 113.07B DKK
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 82.01%
- Operating margin
- 46.15%
- Net margin
- 33.94%
Revenue / Net income
Revenue Net income Net margin
Novo-Nordisk A revenue breakdown
By region
FY2023
63.4%North America23.6%EMEA13.0%Rest of World
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| North America | 136.63B | 63.4% | +50.0% |
| EMEA | 50.87B | 23.6% | +15.0% |
| Rest of World | 28.08B | 13.0% | +10.5% |
How Novo-Nordisk A makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue309.06B 100.0%
Cost of revenue58.79B 19.0%
Gross profit250.28B 81.0%
Research and development52.04B 16.8%
Selling and administration70.28B 22.7%
Other operating expenses300.00M 0.1%
Operating income127.66B 41.3%
Tax28.11B 9.1%
Net income102.43B 33.1%
FY2025, in DKK. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in DKK. Each band is as wide as its money; the percentage is its share of revenue.
Novo-Nordisk A dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 1.16 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 2.83%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 47.72%
- Frequency
- Semi-annual
- Last payment
- 0.58 USD
- Last ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 17 Aug 2026
- Last payment date
- 25 Aug 2026
Dividends per share
Novo-Nordisk A financial health
- Cash and short-term investments
- 49.18B DKK
- Total debt
- 134.48B DKK
- Net cash
- -85.30B DKK
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 46.32B DKK
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 0.84
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.62
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 7 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.74
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Novo-Nordisk A ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 7.41%
- Institutional holders
- 1,456 (+84)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 71.58%
Who owns the shares
Institutions 7.4% Others 92.6%
As of 30 Jun 2026
Shares free to trade
Free float 3.16B shares ·71.6% Closely held 1.25B shares ·28.4%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)
Arincen
Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill
Arincen
Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies
Arincen
Europe’s Biggest Companies Fall Further Behind US Rivals
Title: Novo/Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.